Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3371
Name chondrosarcoma
Definition A bone sarcoma that has_material_basis_in cells derived from transformed cells that produce cartilage.
Source DiseaseOntology.org
Alt Ids DOID:3370
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma chondrosarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 mutant Dasatinib chondrosarcoma resistant detail...
IDH1 R132C Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 R132G Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 R132L Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 R132S Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 act mut Ivosidenib chondrosarcoma sensitive detail...
MLH1 negative Pembrolizumab chondrosarcoma sensitive detail...
MSH6 negative Pembrolizumab chondrosarcoma sensitive detail...
IDH1 R132S Olaparib chondrosarcoma predicted - sensitive detail...
IDH1 R132C Olaparib chondrosarcoma predicted - sensitive detail...
IDH2 R172S Ceralasertib + Olaparib chondrosarcoma sensitive detail...
IDH1 act mut Olutasidenib chondrosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed USA 0
NCT02389244 Phase II Regorafenib A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Recruiting FRA 0
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Completed ITA | GBR | ESP 0
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed USA | GBR | FRA | ESP | AUS 1
NCT04040205 Phase II Abemaciclib Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Recruiting USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04278781 Phase II Ivosidenib AG-120 in People With IDH1 Mutant Chondrosarcoma Recruiting USA 0
NCT04340843 Phase II Belinostat + Guadecitabine Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Active, not recruiting USA 0
NCT04458922 Phase II Atezolizumab Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma Active, not recruiting USA | CAN 0
NCT04521686 Phase I LY3410738 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting USA | FRA | ESP | AUS 5
NCT04784247 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04950075 Phase II INBRX-109 Study of INBRX-109 in Conventional Chondrosarcoma Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 1
NCT05039801 Phase I Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05131386 Phase II Dexamethasone + Trabectedin Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) Recruiting ESP 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT06127407 Phase III Ivosidenib Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER) Recruiting USA | CAN | AUS 2
NCT06176989 Phase II Enasidenib Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Recruiting USA 0